Want to see BRTX full AI Analyst Report?
BRTX Stock Chart & Stats
$0.29
-$0.01(-4.48%)
At close: 4:00 PM EDT
$0.29
-$0.01(-4.48%)
Day’s Range― - ―
52-Week Range$0.16 - $1.89
Previous Close$0.29
Volume676.57K
Average Volume (3M)417.77K
Market Cap
$5.22M
Enterprise Value$514.34K
Total Cash (Recent Filing)$3.59M
Total Debt (Recent Filing)$34.52K
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Aug 18, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.23
Shares Outstanding25,478,170
10 Day Avg. Volume225,011
30 Day Avg. Volume417,769
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)29.75
Price to Sales (P/S)29.50
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.10
Enterprise Value/Revenue1.44
Enterprise Value/Gross Profit1.56
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)$2.50M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Effectively No DebtEffectively zero reported debt reduces interest burden and lowers near-term solvency risk, giving management more flexibility to prioritize R&D or financing terms. Over 2–6 months this structural low-leverage profile improves optionality when raising capital or negotiating lender covenants.
High Trailing Gross MarginA ~63% gross margin indicates favorable underlying product/service economics for the company's cell-based therapies. If the company can sustain or scale revenue without proportionate COGS increases, this margin gives a durable pathway to improve operating leverage long term, assuming R&D and SG&A are controlled.
Board And Leadership Reconfiguration With Experienced CEO And Independent DirectorsInstalling an experienced CEO and adding independent directors with healthcare and commercial expertise strengthens governance and oversight. Structurally, improved board composition and leadership can accelerate strategic prioritization, commercial partnerships, and governance robustness over the medium term.
Bears Say
Persistent, Heavy Cash BurnSustained negative operating and free cash flow of roughly -$12M TTM creates structural funding pressure relative to the company's tiny revenue base. Over months this requires recurring external financing, raising dilution risk and potentially constraining R&D timelines or commercialization efforts if capital is scarce or costly.
Tiny And Declining Revenue BaseA very small revenue base that declined ~51% YoY limits the company's ability to absorb fixed costs and scale operations. Without durable revenue recovery, operating losses will persist and the path to commercial viability and self-funded R&D remains prolonged and dependent on successful clinical or commercial milestones.
Governance Disruption And Elevated Dilution RiskA massive increase in authorized shares plus executive resignations and a board investigation create structural governance and dilution overhangs. This weakens shareholder protections and signals elevated likelihood of future equity financing or share-based compensation, complicating long-term investor alignment and strategic continuity.
BioRestorative Therapies News
BRTX FAQ
What was Biorestorative Therapies, Inc.’s price range in the past 12 months?
Biorestorative Therapies, Inc. lowest stock price was $0.16 and its highest was $1.89 in the past 12 months.
What is Biorestorative Therapies, Inc.’s market cap?
Biorestorative Therapies, Inc.’s market cap is $5.22M.
When is Biorestorative Therapies, Inc.’s upcoming earnings report date?
Biorestorative Therapies, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 15 days.
How were Biorestorative Therapies, Inc.’s earnings last quarter?
Biorestorative Therapies, Inc. released its earnings results on May 20, 2026. The company reported -$0.2 earnings per share for the quarter, the consensus estimate of -$0.2 by $0.
Is Biorestorative Therapies, Inc. overvalued?
According to Wall Street analysts Biorestorative Therapies, Inc.’s price is currently Overvalued.
Does Biorestorative Therapies, Inc. pay dividends?
Biorestorative Therapies, Inc. does not currently pay dividends.
What is Biorestorative Therapies, Inc.’s EPS estimate?
Biorestorative Therapies, Inc.’s EPS estimate is -0.1.
How many shares outstanding does Biorestorative Therapies, Inc. have?
Biorestorative Therapies, Inc. has 25,478,170 shares outstanding.
What happened to Biorestorative Therapies, Inc.’s price movement after its last earnings report?
Biorestorative Therapies, Inc. reported an EPS of -$0.2 in its last earnings report, expectations of -$0.2. Following the earnings report the stock price went down -7.65%.
Which hedge fund is a major shareholder of Biorestorative Therapies, Inc.?
Currently, no hedge funds are holding shares in BRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Biorestorative Therapies, Inc.
BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.
Technical Analysis
Ownership Overview
1.46% Insiders
0.22% Mutual Funds
0.11% Other Institutional Investors
98.16% Public Companies and
Individual Investors